Len-TACE — Competitive Intelligence Brief

Len-TACE (Len-TACE) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Multi-kinase inhibitor (combined with transarterial chemoembolization). Area: Oncology.

phase 3 Multi-kinase inhibitor (combined with transarterial chemoembolization) FGFR, VEGFR, RET, KIT Oncology Small molecule

Target snapshot

Len-TACE (Len-TACE) — Second Affiliated Hospital of Guangzhou Medical University. Len-TACE combines lenvatinib (a multi-kinase inhibitor) with transarterial chemoembolization (TACE) to target hepatocellular carcinoma through dual mechanisms of kinase inhibition and localized chemotherapy delivery.

Comparator set (5 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Len-TACE TARGET	Len-TACE	Second Affiliated Hospital of Guangzhou Medical University	phase 3	Multi-kinase inhibitor (combined with transarterial chemoembolization)	FGFR, VEGFR, RET, KIT
DEB-TACE plus Lenvatinib	DEB-TACE plus Lenvatinib	Guangxi Medical University	phase 3	Combination therapy: locoregional chemotherapy + multi-kinase inhibitor	DEB-TACE: topoisomerase II (doxorubicin); Lenvatinib: FGFR, VEGFR, RET, KIT, PDGFR
Placebo matching lenvatinib	Placebo matching lenvatinib	Merck Sharp & Dohme LLC	phase 3	Multi-targeted tyrosine kinase inhibitor	FGFR, VEGFR, RET, KIT
Adjuvant tislelizumab plus lenvatinib	Adjuvant tislelizumab plus lenvatinib	Guangxi Medical University	phase 3	PD-1 inhibitor + multi-targeted tyrosine kinase inhibitor combination	PD-1 (tislelizumab); FGFR, VEGFR, RET, KIT (lenvatinib)
Lenvatinib, sintilimab plus TACE	Lenvatinib, sintilimab plus TACE	Second Affiliated Hospital of Guangzhou Medical University	phase 3	Multi-kinase inhibitor + PD-1 inhibitor + locoregional chemotherapy	FGFR, VEGFR, RET, KIT (lenvatinib); PD-1 (sintilimab)
Lenvatinib plus TACE	Lenvatinib plus TACE	Second Affiliated Hospital of Guangzhou Medical University	phase 3	Multi-targeted tyrosine kinase inhibitor (in combination with transarterial chemoembolization)	FGFR, VEGFR, RET, KIT, and other receptor tyrosine kinases

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Multi-kinase inhibitor (combined with transarterial chemoembolization) class)

1. Second Affiliated Hospital of Guangzhou Medical University · 1 drug in this class